By attaching two kinds of antibody fragments to membrane-derived globules, researchers selectively delivered CRISPR-Cas9, guide RNA and a transgene to T-cells in living mice to create CAR T-cells. While this technique could make it easier to create CAR T-cells in vivo for cancer therapy, the ultimate goal is to selectively target CRISPR-filled 'enveloped delivery vehicles' to any type of cell and avoid the ex vivo cell editing now used in current gene therapies.